Bart Jan Cornelissen serves as the Chief Financial Officer at Xencor, Inc., a prominent biotechnology company focused on the discovery and development of engineered monoclonal antibodies for the treatment of cancer and other serious diseases. With a robust background in finance and strategic planning within the life sciences industry, Cornelissen has been instrumental in guiding Xencor through various stages of growth and development. He joined Xencor in 2016 and has since played a pivotal role in steering the company's financial strategy, ensuring its sustainability and growth in a competitive market. Before joining Xencor, Cornelissen held several key positions that honed his expertise in financial management and corporate strategy. Notably, he served as the Chief Financial Officer at Anacor Pharmaceuticals, where he was part of the leadership team that successfully took the company public and later facilitated its acquisition by Pfizer. His strategic foresight and adeptness at navigating complex financial landscapes have been crucial in his career. At Xencor, Cornelissen oversees all financial aspects of the company, including financial planning and analysis, accounting, investor relations, and treasury management. His leadership has been vital in securing funding and partnerships that have propelled Xencor's innovative research and development efforts forward.